Background: The objective of this study was to evaluate the feasibility and diagnostic value of 18F-fluorodeoxyglucose\npositron emission tomography/computed tomography (18F-FDG PET/CT) and 99mTc-methylenediphosphonate (MDP)\nwhole-body bone scanning (BS) for the detection of osteolytic bone metastases.\nMethods: Thirty-four patients with pathologically confirmed malignancies and suspected osteolytic bone metastases\nunderwent 18F-FDG PET/CT and 99mTc-MDP whole-body BS within 30 days. The sensitivity, specificity, and accuracy with\nrespect to the diagnosis of osteolytic bone metastases and bone lesions were compared between the two imaging\nmethods.\nResults: The sensitivity, specificity, and accuracy of 18F-FDG PET/CT for the diagnosis of osteolytic bone metastases\nwere 94.3% (95% confidence interval [CI], 91.6ââ?¬â??96.2%), 83.3% (95% CI, 43.6ââ?¬â??96.9%), and 94.2% (95% CI, 91.5ââ?¬â??96.1%),\nrespectively. It was found that 99mTc-MDP whole-body BS could discriminate between patients with 50.2% (95% CI,\n45.4ââ?¬â??55.1%) sensitivity, 50.0% (95% CI, 18.8ââ?¬â??81.2%) specificity, and 50.2% (95% CI, 45.5ââ?¬â??55.1%) accuracy. 18F-FDG PET/CT\nachieved higher sensitivity, specificity, and accuracy in detecting osteolytic bone metastases than 99mTc-MDP wholebody\nBS (p<0.001).\nConclusions: F-FDG PET/CT has a higher diagnostic value than 99mTc-MDP whole-body BS in the detection of osteolytic\nbone metastases, especially in the vertebra.
Loading....